TNF-α

16 Items

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. Ubiquitin ligase inducer

    Lenalidomide is a derivative of thalidomide. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of the micro environment support for tumor cells, and immunomodulatory role. It induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.
  2. TNF-alpha inhibitor

    Pomalidomide is a derivative of thalidomide and acts as an immunomodulator.
  3. E3 ubiquitin ligase inhibitor

    Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.
  4. RIPK1 inhibitor

    Necrostatin-1 is an ATP-competitive, allosteric inhibitor of receptor-interacting protein kinase 1 (RIPK1) (EC50 = 182 nM).
  5. N-SMase inhibitor

    GW4869 is a cell permeable, selective inhibitor of N-SMase (neutral sphingomyelinase).

  6. TNFα inhibitor

    C87 is a novel small-molecule TNFα inhibitor; potently inhibits TNFα-induced cytotoxicity with an IC50 of 8.73 μM.
  7. NF-κB inhibitor

    QNZ inhibits the activation of the transcription factor NF-κB and has been used to investigate NF-κB signaling.
  8. Necroptosis inhibitor

    Necrostatin 2 is a potent necroptosis inhibitor with EC50 of 50 nM.
  9. Necroptosis inhibitor

    Necrostatin 2 is a potent necroptosis inhibitor with EC50 of 50 nM.
  10. Necroptosis inhibitor

    Necrostatin 2 is a potent necroptosis inhibitor with EC50 of 50 nM.
  11. NGF inhibitor

    Ro 08-2750 is a potent and selective Nerve growth factor (NGF) inhibitor that binds the NGF dimer (KD ~ 1 μM).
  12. TNF receptor inhibitor

    AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). Inhibiting an immediate TCR signal has promise for treating a broad spectrum of human T cell-mediated autoimmune and inflammatory diseases.
  13. TRAF6-Ubc13 inhibitor

    C25-140, a first-in-class, fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity.
  14. CD40-CD40L inhibitor

    DRI-C21045 is a potent and selective inhibitor of the CD40-CD40L costimulatory protein-protein interaction (PPI) with an IC50 of 0.17 ?M.
  15. TNF-alpha inhibitor

    CPI-1189 (REN 1654, REN 1189) is the proapoptotic cytokine tumor necrosis factor (TNF) alpha inhibitor.
  16. TRPV1 antagonist and TNF-alpha production inhibitor

    LASSBio-1135 is a dual TRPV1 antagonist and TNF-alpha production inhibitor.

16 Items

per page
Set Descending Direction